Having trouble viewing email? View in web browser
The Power of Cytology and Molecular Diagnostics Combined
Now working as one company, Hologic and Gen-Probe have brought together the world of cytology and molecular diagnostics. We revolutionized cervical screening with the ThinPrep Pap test. Today we are the only company to offer a complete solution for cervical screening, which includes Pap and HPV testing.

Our Aptima HPV and Cervista HPV tests target the oncogenes E6 and E7, the genes responsible for cervical disease progression. Both HPV test solutions from Hologic help to identify the 14 most prevalent high-risk HPV types and run on fully-automated platforms to deliver proven clinical performance.

The Aptima HPV test detects mRNA from the E6/E7 oncogenes identifying high-risk HPV infections.1 The Aptima test has also shown:

  Excellent sensitivity – demonstrating equivalent sensitivity to DNA based HPV tests in multiple clinical studies involving over 50,000 women worldwide2
  Improved specificity to DNA based HPV tests – reducing false positives by 24% in the clinical trial3-15
The combination of the Aptima HPV test's sensitivity and specificity may help identify women at risk and may minimize the potential for over-treatment.

Learn more about Hologic’s complete cervical screening solutions at the Hologic stand, #23 or contact us at info@hologic.com.

Hologic Satellite Symposium
The Past, Present and Future of Cervical Screening

November 3, 2013


Learn more about the role of cervical cancer screening and HPV testing in today’s healthcare environment.

The Aptima HPV Test  |  The Cervista HPV Test  |  The ThinPrep Pap Test
1. Tinelli A, et al. Curr Pharm Biotechnol. 2009 Dec;10(8):767-71
2. Cuschieri K, et al. J Med Virol. 2004 May;73(1):65-70
3. Aptima® HPV Assay package insert #503744EN Rev A 2012
4. Dockter J, et al. J Clin Virol. 2009;45(S1): S55-S61
5. Szarewski A, et al. Cancer Epidimiol Biomarkers Prev. 2008; 17(11): 3033-42
6. Szarewski A, et al. J Clin Micro. 2012; 50(6): 1867-73
7. Ruschenbach M, et al. Gynecol Oncol. 2010; 119(1): 98-105.
8. Clad A, et al. J Clin Micro. 2011; 49(3): 1071-76
9. Ratnam S, et al. J Clin Micro. 2011; (49(2): 557-64
10. Wu R, et al. Intl J Gyn Cancer. 2010; 20(8): 1411-14
11. Monsonego J, et al. Intl J Cancer. 2011; 129: 691-701
12. Cuzick, J et al. Br J Cancer. 2013 March 5; 108(4): 908–913.
13. Iftner, T et al. Comparison of Aptima and HC2 in a routine screening trial in Germany with follow up [abstract]. International Papillomavirus Conference; 2012 Nov 30-Dec 6; San Juan, Puerto Rico.
14. Ovestad I, et al. Gynecol Oncol. 2011; 123(2): 278-283.
15. APTIMA HPV Assay package insert #503744EN Rev A 2012,Table 22

  Hologic, Inc., Aptima, Cervista and ThinPrep are trademarks and/or registered trademarks of Hologic and/or its subsidiaries in the U.S. and/or other countries. This information is intended for medical professionals in the U.S. and other markets, and is not intended as a product solicitation or promotion where such activities are prohibited. Because Hologic materials are distributed through websites, eBroadcasts and tradeshows, it is not always possible to control where such materials appear. For specific information on what products are available for sale in a particular country, write to womenshealth@hologic.com.